INCENTIVIZING ORGANIZATIONS TO DEVELOP A VACCINE FOR USE AGAINST *Brucella melitensis* IN SMALL RUMINANTS ACROSS THE DEVELOPING WORLD

**THE BRUCELLOSIS VACCINE PRIZE**
US $30 million prize competition

HAVE A WINNING IDEA?

Learn more and apply online:
www.brucellosisvaccine.org

Questions? brucellosis@galvmed.org

Follow us @AgResults | @GALVmed
CALLING ALL ANIMAL HEALTH INNOVATORS

The Brucellosis Vaccine Prize is a global competition funded by AgResults and implemented by the Global Alliance for Livestock Veterinary Medicines (GALVmed).

It invites vaccine developers (‘Solvers’) to submit their proposals for – and ultimately develop – a suitable vaccine that is efficacious, safe and viable for use against *Brucella melitensis* in small ruminants across the developing world.

**Are you a Solver?**
The competition is open to any organization that has the ability to develop vaccines. That may include animal health, biotech and pharmaceutical companies, as well as academic and research institutions. Organizations are welcome to partner with third parties if they need additional expertise or capabilities.

**THE CHALLENGE: BRUCELLOSIS**

Brucellosis is a costly disease that affects livestock and causes abortions, infertility, decreased milk production and weight loss.

The annual impact of brucellosis to smallholder farmers (SHFs) in South Asia and Sub-Saharan Africa is estimated at US $500 million per year.

It is a costly, zoonotic disease – there are approximately 500,000 new human cases of brucellosis reported annually.

There are challenges and drawbacks associated with current vaccines, including safety in pregnant animals, variable efficacy, and potential harm to humans.

**BY ENTERING THE COMPETITION, SOLVERS HAVE THE OPPORTUNITY TO:**

- **Win a share of the US $30 million total prize fund**
  - Phased milestone prizes help to cover R&D costs
  - Help to lead brucellosis control in the developing world

- **Have a transformative impact on the lives of 600 million people in developing countries whose livelihoods depend on livestock**
  - Helping to improve both animal and human health

- **Extend your reach into emerging markets**

This is not an official competition document, all prizes and all requirements regarding the competition are subject to the official Competition Rules.
BRUCELLOSIS VACCINE PRIZE JOURNEY

Phase 1: Application Phase
Develop the idea
Submit initial application

Milestone Payment 1
US $100,000
Applications are reviewed quarterly and milestone payments are awarded to the best 10 solvers who meet requirements

Do you need development/commercialization assistance?

No
Yes

Supply evidence of support/commitment from relevant partner organization

Final Phase: Take vaccine candidate to a registered product meeting MVP Requirements

Best in Class Prize: US $5 million
If any one of the best in class criteria are met within 1 year of the Grand Prize award

Grand Prize: US $20 million
For the first solver that registers a vaccine meeting the MVP requirements

Phase 2: Solving Phase
Proof-of-concept
Meet efficacy and safety requirements for milestone 2

Milestone Payment 2
US $1 million
Awarded to the first 4 solvers who meet requirements

GRAND PRIZE FOR THE FIRST SOLVER THAT REGISTERS A VACCINE MEETING THE MVP

To win the Grand Prize of US $20 million, the winning vaccine will need to meet all the requirements set out in the Minimum Viable Product (MVP), and will ideally overcome all current hurdles that inhibit the safety and efficacy of current B. melitensis vaccines in developing countries.

Full details of the MVP requirements can be found in Appendix 3 of the official Competition Rules.

To win the Grand Prize of US $20 million, the winning vaccine will need to meet all the requirements set out in the Minimum Viable Product (MVP), and will ideally overcome all current hurdles that inhibit the safety and efficacy of current B. melitensis vaccines in developing countries.

Full details of the MVP requirements can be found in Appendix 3 of the official Competition Rules.

Considerations for the MVP include:

- **SPECIES** B. melitensis in sheep or goats
- **SAFE** Safe for pregnant animals (Less than 5% abortion)
- **EFFICACIOUS** More than 80% animals protected
- **SMALL HOLDER FARMER FRIENDLY** Affordable cost, long shelf life

ADDITIONAL US $5 MILLION PRIZE OPPORTUNITY FOR BEST IN CLASS

A US $5 million prize will be available to solvers that develop a vaccine that meets the MVP requirements and any one of the best in class criteria. The Best in Class prize will be open to Solvers for one year after the award of the Grand Prize.

Best in Class criteria include:

- **CROSS-SPECIES PROTECTION** Protect against both B. melitensis in small ruminants and B. abortus in cattle
- **SAFETY** Providing maximum human and animal safety (e.g. inactivated)
- **THERMORESISTANCE** Effective at 45 degrees centigrade for 3 weeks
- **CURATIVE** Curative/therapeutic effect on infected animals
SUBMIT YOUR APPLICATION EARLY

Starting on November 18, 2016, applications will be evaluated on a quarterly basis for one year for Milestone 1 Payments. This Milestone Prize of $100K will be awarded to a maximum of 10 of the best Solvers.

Solvers are therefore advised to submit applications as early as possible to increase the chances of being eligible for this Phase 1 prize.

LEARN MORE AND APPLY ONLINE: www.brucellosisvaccine.org

AgResults is a US $118 million multilateral initiative between the governments of Australia, Canada, the UK and US and the Bill & Melinda Gates Foundation to incentivize and reward high-impact agricultural innovations that promote global food security, health, and nutrition and benefit smallholder farmers.

The implementation of the Brucellosis Vaccine Prize will be managed by the Global Alliance for Livestock Veterinary Medicines (GALVmed), an international not-for-profit company. GALVmed, through its partners, makes livestock vaccines, medicines and diagnostics accessible and available to smallholder farmers in developing countries.